ASSESSMENT OF GROWTH-HORMONE (GH) AXIS IN TURNERS SYNDROME USING 24-HOUR INTEGRATED CONCENTRATIONS OF GH, INSULIN-LIKE GROWTH FACTOR-I, PLASMA GH-BINDING ACTIVITY, GH BINDING TO IM9 CELLS, AND GH RESPONSE TO PHARMACOLOGICAL STIMULATION

被引:36
|
作者
ZADIK, Z
LANDAU, H
CHEN, M
ALTMAN, Y
LIEBERMAN, E
机构
[1] HADASSAH UNIV HOSP, DEPT PEDIAT, ENDOCRINE UNIT, JERUSALEM, ISRAEL
[2] KAPLAN HOSP, ENDOCRINE LAB, IL-76100 REHOVOT, ISRAEL
[3] HEBREW UNIV JERUSALEM, HADASSAH MED SCH, IL-91010 JERUSALEM, ISRAEL
[4] SOROKA MED CTR, PEDIAT ENDOCRINE UNIT, IL-84101 BEER SHEVA, ISRAEL
来源
关键词
D O I
10.1210/jc.75.2.412
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The GH axis was studied in Turner's syndrome (TS) patients. Thirty-seven prepubertal TS patients and 42 normally growing girls (NGG; 5.5-16.3 yr old), of whom 13 were prepubertal, were studied by 24-h continuous blood withdrawal and provocative tests. The 24-h integrated concentrations of GH (IC-GH), FSH (IC-FSH), and insulin-like growth factor-I (IC-IGF-I) as well as the IC-IGF-I/IC-GH ratio were determined. An increase in IC-GH with age and progression of puberty was found in NGG, but not in TS. IC-GH in the NGG was significantly higher than that in age-matched TS patients. Estrogen replacement therapy normalized IC-GH levels in 6 TS patients in whom these levels were subnormal for age. A positive correlation between IC-GH and IC-FSH or IC-estradiol was found in NGG (r = 0.462; P < 0.01), but not in TS patients. The IC-IGF-I/IC-GH ratio was significantly higher in the TS than in the NGG group. Serum GH-binding activity and serum GH binding to IM9 cells in the TS group did not differ from those in the normal group. We hypothesize that the growth retardation of TS results from a combination of insufficient GH secretion, mainly due to sex steroid deficiency, and an end-organ resistance to IGF-1. IGF-I receptor studies are needed to test this speculation about IGF-I resistence.
引用
收藏
页码:412 / 416
页数:5
相关论文
共 50 条
  • [1] ANALYSIS OF 24-HOUR PLASMA PROFILES OF GROWTH-HORMONE (GH)-BINDING PROTEIN, GH GH-BINDING PROTEIN-COMPLEX, AND GH IN HEALTHY-CHILDREN
    CARLSSON, LMS
    ROSBERG, S
    VITANGCOL, RV
    WONG, WLT
    ALBERTSSONWIKLAND, K
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (02): : 356 - 361
  • [2] THE INTERRELATIONSHIP OF GROWTH-HORMONE (GH), LIVER MEMBRANE GH RECEPTOR, SERUM GH-BINDING PROTEIN-ACTIVITY, AND INSULIN-LIKE GROWTH FACTOR-I IN THE MALE-RAT
    BICK, T
    AMIT, T
    BARKEY, RJ
    HERTZ, P
    YOUDIM, MBH
    HOCHBERG, Z
    ENDOCRINOLOGY, 1990, 126 (04) : 1914 - 1920
  • [3] ROLES OF PULSATILITY AND CONTINUITY OF GROWTH-HORMONE (GH) ADMINISTRATION IN THE REGULATION OF HEPATIC GH-RECEPTORS, AND CIRCULATING GH-BINDING PROTEIN AND INSULIN-LIKE GROWTH FACTOR-I
    BICK, T
    HOCHBERG, Z
    AMIT, T
    ISAKSSON, OGP
    JANSSON, JO
    ENDOCRINOLOGY, 1992, 131 (01) : 423 - 429
  • [4] INFLUENCE OF NUTRITION AND BOVINE GROWTH-HORMONE (GH) ON HEPATIC GH BINDING, INSULIN-LIKE GROWTH FACTOR-I AND GROWTH OF LAMBS
    BASS, JJ
    OLDHAM, JM
    HODGKINSON, SC
    FOWKE, PJ
    SAUERWEIN, H
    MOLAN, P
    BREIER, BH
    GLUCKMAN, PD
    JOURNAL OF ENDOCRINOLOGY, 1991, 128 (02) : 181 - 186
  • [5] Lack of effect of methylphenidate on serum growth hormone (GH), GH-binding protein, and insulin-like growth factor I
    Toren, P
    Silbergeld, A
    Eldar, S
    Laor, N
    Wolmer, L
    Koren, S
    Weitz, R
    Inbar, D
    Reiss, A
    Eshet, R
    Weizman, R
    CLINICAL NEUROPHARMACOLOGY, 1997, 20 (03) : 264 - 269
  • [6] CONTRASTING EFFECTS OF ORAL AND TRANSDERMAL ROUTES OF ESTROGEN REPLACEMENT THERAPY ON 24-HOUR GROWTH-HORMONE (GH) SECRETION, INSULIN-LIKE GROWTH FACTOR-I, AND GH-BINDING PROTEIN IN POSTMENOPAUSAL WOMEN
    WEISSBERGER, AJ
    HO, KKY
    LAZARUS, L
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (02): : 374 - 381
  • [7] NONPARALLEL CHANGES OF GROWTH-HORMONE (GH) AND INSULIN-LIKE GROWTH FACTOR-I, INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-3, AND GH-BINDING PROTEIN, AFTER CRANIOSPINAL IRRADIATION AND CHEMOTHERAPY
    NIVOT, S
    BENELLI, C
    CLOT, JP
    SAUCET, C
    ADAN, L
    SOUBERBIELLE, JC
    ZUCKER, JM
    RAPPAPORT, R
    BRAUNER, R
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (03): : 597 - 601
  • [8] SERUM GROWTH-HORMONE (GH)-BINDING PROTEIN AND INSULIN-LIKE GROWTH FACTOR-I LEVELS IN TURNERS SYNDROME BEFORE AND DURING TREATMENT WITH RECOMBINANT HUMAN GH AND ETHINYL ESTRADIOL
    MASSA, G
    BOUILLON, R
    VANDERSCHUERENLODEWEYCKX, M
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (05): : 1298 - 1302
  • [9] SLEEP, AWAKENINGS, AND INSULIN-LIKE GROWTH FACTOR-I MODULATE THE GROWTH-HORMONE (GH) SECRETORY RESPONSE TO GH-RELEASING HORMONE
    VANCAUTER, E
    CAUFRIEZ, A
    KERKHOFS, M
    VANONDERBERGEN, A
    THORNER, MO
    COPINSCHI, G
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (06): : 1451 - 1459
  • [10] Effects of growth hormone (GH) and insulin-like growth factor-I therapy in patients with gene defects in the GH axis
    Riedl, S
    Frisch, H
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2006, 19 (03): : 229 - 236